What is Biosensing Instrument?
Biosensing Instrument operates at the intersection of advanced optics and molecular biology, specializing in the development of label-free interaction instruments. By leveraging Surface Plasmon Resonance (SPR) technology, the company provides researchers with high-precision tools such as the SPRm 200 system. This platform uniquely integrates optical microscopy with SPR, enabling real-time, high-resolution measurement of binding reactions at the cellular membrane level. By serving both the pharmaceutical industry and academic research institutions, the company facilitates critical breakthroughs in drug discovery and chemical sensing. Their portfolio of benchtop instruments is engineered to meet the rigorous demands of modern laboratories, ensuring that complex bioanalytical workflows are both efficient and accurate.
How much funding has Biosensing Instrument raised?
Biosensing Instrument has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in Biosensing Instrument
PPP
Public-Private Partnership
What's next for Biosensing Instrument?
As the company transitions through this late-stage funding phase, the focus shifts toward aggressive market expansion and the refinement of its product ecosystem. The strategic deployment of this capital will likely prioritize the enhancement of R&D capabilities to maintain a competitive edge in label-free detection. Furthermore, Biosensing Instrument is expected to scale its commercial operations, targeting deeper penetration into the pharmaceutical research pipeline where demand for high-fidelity molecular interaction data remains robust. By optimizing its service offerings and expanding its global distribution network, the firm is poised to become a cornerstone provider for next-generation life science research and development.
See full Biosensing Instrument company page
